You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 74 No. 6, December 1956 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Rheumatoid and Lupus-Erythematosus-like Syndromes

Complications of Hydralazine (Apresoline) Therapy for Hypertension

J. GORDON ERICKSON, M.D.; EDGAR A. HINES, JR., M.D.; GERTRUDE L. PEASE, M.D.; LOUIS A. BRUNSTING, M.D.

AMA Arch Derm. 1956;74(6):640-647.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

During the past two years hydralazine hydrochloride (1-hydrazinophthalazine hydrochloride; Apresoline) has been used extensively in the treatment of hypertension. Its reputed ability to reduce arterial pressure through its central action1 and to increase renal circulation2 accounts in part for its usefulness as an antihypertensive agent.

A syndrome, however, appeared among patients using hydralazine, with symptoms which ranged from mild migratory arthralgic pains to symptoms resembling early acute rheumatoid arthritis or acute systemic lupus erythematosus, according to Dustan and his group* and to Perry and Schroeder.{dagger} Other isolated cases reported in the recent literature include those of Manter,7 Feder,8 Reinhardt and Waldron,9 and Shackman and associates.10 Kaufman11 reported a case of pancytopenia due to hydralazine.

This report is an analysis of the late reactions in a group of patients treated with oral administrations of hydralazine . . . [Full Text PDF of this Article]


Author Affiliations

Van Nuys, Calif.; Rochester, Minn.


Footnotes

Submitted for publication Jan. 19, 1956.

Fellow in Dermatology, Mayo Foundation (Dr. Erickson); Section of Medicine (Dr. Hines), Section of Clinical Pathology (Dr. Pease), and Section of Dermatology (Dr. Brunsting), Mayo Clinic and Mayo Foundation. The Mayo Foundation is a part of the Graduate School of the University of Minnesota.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1956 American Medical Association. All Rights Reserved.